Aratana nears approval for canine cancer vaccine
Aratana Therapeutics Inc.'s cancer immunotherapy drug for dogs gained a conditional license from the U.S. Department of Agriculture, the company announced Wednesday. To gain full licensure, Aratana (Nasdaq; PETX) will start another field study in early 2018.
The vaccine initially will be available for purchase at 12 veterinary oncology practices participating in the study. It's designed to treat dogs with bone cancer after the tumor is surgically removed. It works using listeria, a type of bacteria,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Elise Reuter Source Type: news
More News: Biotechnology | Bone Cancers | Cancer | Cancer & Oncology | Cancer Vaccines | Health Management | Immunotherapy | Listeria | Study | Vaccines | Veterinary Research | Veterinary Vaccinations